NTRR Joint Venture Researches Solvent-Free Methods to Create Organic Cannabis Topicals

In order to capitalize on the growing demand for cannabis-infused creams, balms and oils, Neutra Corp. (OTCQB: NTRR) joint venture partner Oceanview Health Services Ltd. will source organic, solvent-free cannabis concentrates for infusion into a new line of topical products.

“Microbe- and pesticide-free topicals are what both consumers and providers want," said NTRR CEO Chris Brown. “In order to meet that demand, Oceanview is working now to source only organic, pesticide-free cannabis crops for these new products. The plan is to turn the plant matter into potent concentrates using only heat and pressure, rather than potentially harmful solvents such as butane or carbon dioxide.”

“By utilizing the cutting-edge ‘rosin tech’ method of concentrate production, Oceanview could soon be creating the best organic topicals in the North American cannabis industry,” he added.

The utilization of innovative, solvent-free production of concentrates and organic cannabis crops is one way in which NTRR and Oceanview plan to differentiate the joint venture’s topical solutions in the highly competitive cannabis market. Once they are proven successful, the joint venture plans to license its formulas and production techniques to government-regulated cannabis businesses across the U.S. and Canada. NTRR expects that the organic, solvent-free formulas will be especially attractive to medical cannabis patients concerned about potential additives and contaminants.

Oceanview Health Services Ltd. is a Canadian nutraceuticals company focused on providing new medicinal solutions utilizing cannabinoids. NTRR formed its joint venture with Oceanview last month. In the new year, NTRR plans to deliver many new offerings for cannabis producers and consumers alike as demand for CBD products and services grows by the day.

About Neutra Corp.

Neutra Corp. is a healthy lifestyle company that specializes in the development and marketing of natural wellness solutions, including cannabis-related products. By providing a variety of new technologies designed to ensure safer, more reliable access to cannabis in approved markets, Neutra Corp. plans to compete alongside GW Pharmaceuticals (OTCBB: GWPRF), INSYS Therapeutics, Inc. (NASDAQ: INSY) and ENDEXX Corp. (OTCBB: EDXC), delivering technological advancements in the cultivation and processing of cannabis in approved markets. For investing information and performance data, please visit www.neutracorp.com.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160107005421/en/